![Aaron Ren](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aaron Ren
Chief Executive Officer at Sironax Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Xiao Dong Wang | M | 61 |
Sironax Ltd.
![]() Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | 7 years |
Auerbach Daniel | M | 66 |
Sironax Ltd.
![]() Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | - |
Ranjeev Krishana | M | 50 |
Sironax Ltd.
![]() Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | - |
Stacie Weninger | M | - |
Sironax Ltd.
![]() Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | - |
Michael Nuoqing Yi | M | - |
Sironax Ltd.
![]() Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | - |
Xiao Huang | M | 39 |
Sironax Ltd.
![]() Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Zheng Bin Yao | M | 58 | 3 years | |
Edward Hu | M | 61 | 3 years | |
Andreas Wicki | M | 64 | 3 years | |
Xiao Meng Tong | M | 50 | 2 years | |
Yan Ling Cao | M | 39 | 3 years | |
Pascal Soriot | M | 64 | 1 years | |
Tyrell J. Rivers | M | 51 | 3 years | |
Christian Nolet | M | 67 | 2 years | |
Jörn Drappa | M | 60 | 3 years | |
Mitchell Chan | M | 43 | 3 years | |
Jim Kastenmayer | M | 52 | 1 years | |
Matthew J. Pietras | M | - | 2 years | |
Jacques Suzanne | F | 53 | 1 years | |
Soraya Madani | M | - | 2 years | |
Kate Surdez | F | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 15 | 71.43% |
China | 6 | 28.57% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Aaron Ren
- Personal Network